<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01583582</url>
  </required_header>
  <id_info>
    <org_study_id>MARE-050312</org_study_id>
    <nct_id>NCT01583582</nct_id>
  </id_info>
  <brief_title>Antihypertensive Effect and Safety of Peptides Derived From Coldwater Shrimp</brief_title>
  <acronym>MARE</acronym>
  <official_title>Assessment on Antihypertensive Effect and Safety of Bioactive Peptides Derived From Coldwater Shrimp (Pandalus Borealis) in Healthy Subjects With Mild or Moderate Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marealis AS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Marealis AS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this proof of concept study is to find out the efficacy of Marealis Refined
      Peptide Concentrate (RPC) from Coldwater Shrimp (Pandalus borealis) containing ACE-inhibiting
      peptides on blood pressure in subjects with mild or moderate hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in systolic blood pressure</measure>
    <time_frame>from baseline after 8 weeks of treatment</time_frame>
    <description>change from baseline after 8 weeks of treatment in systolic office blood pressure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in diastolic blood pressure</measure>
    <time_frame>from baseline after 8 weeks of treatment</time_frame>
    <description>change from baseline after 8 weeks of treatment in diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean systolic blood pressure</measure>
    <time_frame>at the end of a 8-week treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean diastolic blood pressure</measure>
    <time_frame>at the end of a 8-week treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in systolic blood pressure</measure>
    <time_frame>from baseline after 4 weeks treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diastolic blood pressure</measure>
    <time_frame>from baseline after 4 weeks treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diastolic blood pressure</measure>
    <time_frame>from baseline after 2 weeks treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean heart rate</measure>
    <time_frame>at the end of a 8-week treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean fasting plasma glucose concentration</measure>
    <time_frame>at the end of a 8-week treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean fasting plasma lipids concentration</measure>
    <time_frame>at the end of a 8 week treatment</time_frame>
    <description>plasma total cholesterol, HDL-cholesterol, LDL-cholesterol and total triglycerides concentration, respectively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean serum C-reactive protein</measure>
    <time_frame>at the end of a 8-week treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood count</measure>
    <time_frame>at the end of a 8-week treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma glutamyltransferase</measure>
    <time_frame>at the end of a 8-week treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma creatinine</measure>
    <time_frame>at the end of a 8-week treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma sodium concentration</measure>
    <time_frame>at the end of a 8-week treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma potassium concentration</measure>
    <time_frame>at the end of a 8-week treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>during the 8-week treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in systolic blood pressure</measure>
    <time_frame>from the baseline after 2 weeks treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Hypertension</condition>
  <condition>Blood Pressure</condition>
  <arm_group>
    <arm_group_label>Refined peptide concentrate, 1200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Refined peptide concentrate, 1 200 mg, once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Refined peptide concentrate, 2 x 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Refined peptide concentrate, 600 mg, twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Refined peptide concentrate, 0 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Marealis Refined Peptide Concentrate</intervention_name>
    <description>1200 mg per os, once a day, 8 weeks</description>
    <arm_group_label>Refined peptide concentrate, 1200 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Marealis Refined Peptide Concentrate</intervention_name>
    <description>600 mg per os, twice a day, 8 weeks</description>
    <arm_group_label>Refined peptide concentrate, 2 x 600 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Marealis Refined Peptide Concentrate</intervention_name>
    <description>0 mg per os, daily, 8 weeks</description>
    <arm_group_label>Refined peptide concentrate, 0 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  mild or moderate hypertension (systolic blood pressure 130 - 160 mmHg and diastolic
             blood pressure ≤ 100 mmHg)

          -  age 30 - 75 years

          -  body weight ≥ 60 kg

          -  stable body weight

          -  use of effective contraception in women of childbearing potential

        Exclusion Criteria:

          -  body mass index ≥ 35

          -  antihypertensive drug treatment, regular high dose NSAID treatment and the use of
             cyclosporine or tacrolimus

          -  diabetes (type 1 and 2)

          -  anemia, abnormal electrolytes, proteinuria, abnormal liver, kidney and thyroid
             function, clinically significant biochemistry, any other clinically significant
             hematology and/or biochemistry at the investigator's discretion

          -  cardiovascular disease (myocardial infarction, unstable angina pectoris, coronary
             artery bypass graft, percutaneous transluminal coronary angioplasty, temporal ischemic
             attack within six months prior to screening) including stroke and congestive heart
             failure

          -  secondary hypertension history of cancer or malignant disease within the past five
             years

          -  any metabolic disease, gastrointestinal disorder or other clinically significant
             disease/disorder which in the investigator's opinion could interfere with the results
             of the study or the safety of the subjects

          -  fish and other seafood allergies, citrus allergy, multiple food allergies

          -  alcohol abuse

          -  smokers and tobacco/snuff/nicotine users

          -  consumption of food supplements targeted to blood pressure lowering within 30 days
             before randomization

          -  pregnant and lactating mothers, women, planning for pregnancy during the study

          -  participation in clinical trials 30 days prior to this study and participation in
             other clinical intervention
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Essi S Sarkkinen, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Oy Foodfiles Ltd</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sakari A Nieminen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oy Foodfiles Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oy Foodfiles Ltd</name>
      <address>
        <city>Kuopio</city>
        <zip>70210</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2012</study_first_submitted>
  <study_first_submitted_qc>April 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2012</study_first_posted>
  <last_update_submitted>January 30, 2013</last_update_submitted>
  <last_update_submitted_qc>January 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Marealis AS</investigator_affiliation>
    <investigator_full_name>Niina Tapola</investigator_full_name>
    <investigator_title>Project Manager</investigator_title>
  </responsible_party>
  <keyword>randomized double-blind placebo-controlled study</keyword>
  <keyword>peptide concentrate</keyword>
  <keyword>Coldwater Shrimp</keyword>
  <keyword>antihypertensive effect</keyword>
  <keyword>mild hypertension</keyword>
  <keyword>moderate hypertension</keyword>
  <keyword>blood pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antihypertensive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

